Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum

Journal of Nephrology

Volumn 26, Issue 6, 2013, Pages 1151-1159

  Lacquaniti, Antonio ^a   Chirico, Valeria ^a   Mondello, Stefania ^a   Buemi, Antoine ^a   Lupica, Rosaria ^a   Fazio, Maria R ^a   Buemi, Michele ^a   Aloisi, Carmela ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Biocompatibility; Cancer antigen 125; Neutrophil gelatinase associated lipocalin; Peritoneal dialysis; Peritoneal solutions; Peritoneal ultrafiltration failure; Peritonitis

Indexed keywords

ANTIBIOTIC AGENT; CA 125 ANTIGEN; ICODEXTRIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CEFAZOLIN; CEFTAZIDIME; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; ITALY; LEUKOCYTE COUNT; MALE; MESOTHELIUM CELL; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FLUID; PERITONEAL ULTRAFILTRATION FAILURE; PERITONEUM; PERITONITIS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT DURATION; TREATMENT FAILURE; ULTRAFILTRATION; AGED; AREA UNDER THE CURVE; ASCITES FLUID; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; PATHOLOGY;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASCITIC FLUID; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CEFAZOLIN; CEFTAZIDIME; FEMALE; HUMANS; LEUKOCYTE COUNT; LIPOCALINS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PERITONITIS; PROTO-ONCOGENE PROTEINS; ROC CURVE; TREATMENT FAILURE;

EID: 84889661455     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000271     Document Type: Article

References (32)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;12(12):2587-2593.
2. Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20:5-21.
3. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int. 1994;14(Suppl 3):S21-S28.
4. Pajek J, Kveder R, Bren A, et al. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant. 2009;24(5):1617-1625.
5. Chaudhary K, Khanna R. Biocompatible peritoneal dialysis solutions: do we have one? Clin J Am Soc Nephrol. 2010; 5(4):723-732.
6. Li PK, Szeto CC, Piraino B, et al. International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30(4):393-423.
7. Rodrigues AS, Almeida M, Fonseca I, et al. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation. Nephrol Dial Transplant. 2006;21(3):763-769.
8. Rodrigues AS, Martins M, Korevaar JC, et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am J Nephrol. 2007; 27(1):84-91.
9. Yamagata K, Tomida C, Koyama A. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19(2):131-137.
10. Opatrna S, Lysak D, Trefil L, Parker C, Topley N. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int. 2012;32(1):37-44.
11. Lopes Barreto D, Coester AM, Noordzij M, et al. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26(11):3739-3744.
12. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595-605.
13. Leung JC, Lam MF, Tang SC, et al. Roles of neutrophil gelatinase-associated lipocalin in continuous ambulatory peritoneal dialysis-related peritonitis. J Clin Immunol. 2009;29(3): 365-378.
14. Keane WF, Bailie GR, Boeschoten E, et al. International Society for Peritoneal Dialysis. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int. 2000;20(4):396-411.
15. Szeto CC, Chow KM, Leung CB, et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int. 2001;59(6): 2309-2315.
16. Piraino B, Bailie GR, Bernardini J, et al. ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25(2):107-131.
17. Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138-147.
18. Fahim M, Hawley CM, McDonald SP, et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis. 2010;55(4):690-697.
19. Buemi M, Aloisi C, Cutroneo G, Nostro L, Favaloro A. Flowing time on the peritoneal membrane. Nephrol Dial Transplant. 2004;19(1):26-29.
20. Bajo MA, Selgas R, Castro MA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int. 2000;20(6):742-747.
21. Mondello S, Buemi M, Mazzon E, Aloisi C. Lymphocytic vasculitis associated with icodextrin. Perit Dial Int. 2007;27(6): 712-715.
22. Ha H, Yu MR, Choi HN, et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int. 2000;20(Suppl 5): S10-S18.
23. Parikova A, Zweers MM, Struijk DG, Krediet RT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial. 2003;19:186-190.
24. van Esch S, Zweers MM, Jansen MA, de Waart DR, van Manen JG, Krediet RT. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit Dial Int. 2004;24(6):554-561.
25. Cho JH, Hur IK, Kim CD, et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrol Dial Transplant. 2010;25(6):1964-1973.
26. Breborowicz A, Breborowicz M, Pyda M, Połubinska A, Oreopoulos D. Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin Pract. 2005;100(2):c46-c51.
27. Fusshöller A, Grabensee B, Plum J. CA125 in the effluent of chronic peritoneal dialysis (PD) patients: relation to transport parameters, peritonitis, PD duration, and regime. Perit Dial Int. 2000;20:S7.
28. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21(6):560-567.
29. Mondello S, Mazzon E, Di Paola R, et al. Erythropoietin suppresses peritoneal fibrosis in rat experimental model. Eur J Pharmacol. 2009;604(1-3):138-149.
30. Mondello S, Mazzon E, Di Paola R, et al. Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model. Shock. 2009;32(3):332-339.
31. Del Peso G, Jim'enez-Heffernan JA, Bajo MA, et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int. 2008;73:S26-S33.
32. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2003;23(6):530-541.